National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans

References

• Ritchlin CT. Mechanisms of erosion in rheumatoid arthritis. J Rheumatol 2004;31:1229-37
   PubMedGoogle Scholar
• Cook AD, Visvanathan K. Molecular targets in immune-mediated diseases: focus on rheumatoid arthritis. Expert Opin Therap Targets 2004;8:375-90
   PubMed Web of Science ®Google Scholar
• Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108
   PubMed Web of Science ®Google Scholar
• Kalyoncu U, Dougados M, Daures JP, et al. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2009;68:183-90
   PubMed Web of Science ®Google Scholar
• Isik A, Koca SS, Ozturk A, et al. Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:872-8
   PubMed Web of Science ®Google Scholar
• Sheehy C, Murphy E, Barry M. Depression in rheumatoid arthritis – underscoring the problem. Rheumatology (Oxford) 2006;45:1325-7
   PubMed Web of Science ®Google Scholar
• Yelin E. Work disability in rheumatic diseases. Curr Opin Rheumatol 2007;19:91-6
   PubMed Web of Science ®Google Scholar
• Birnbaum H, Pike C, Kaufman R, et al. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin 2010;26:77-90
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan V, Huang XY, et al. Influence of rheumatoid arthritis on employment, function, and productivity in a nationally representative sample in the United States. J Rheumatol 2010;37:544-9
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patient with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
   PubMed Web of Science ®Google Scholar
• Breedveld F, Emery P, Ferraccioli G, et al. Clinical response and remission at 12, 24, and 52 weeks with the combination of etanercept and methotrexate in the treatment of early active rheumatoid arthritis in the COMET trial. Ann Rheum Dis 2008;67(2 Suppl):1
   PubMedGoogle Scholar
• Van der Heijde D, Klareskog L, Landewe R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928-39
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet 2008;372:375-82
   PubMed Web of Science ®Google Scholar
• HUMIRA (adalimumab) PI, 03/2011. Abbott Laboratories
   Google Scholar
• REMICADE (infliximab) PI, 04/2011. Centocor Ortho Biotech Inc
   Google Scholar
• ENBREL (etanercept) PI, 05/2011. Manufactured by Immunex Corporation. Marketed by Amgen Inc. and Pfizer Inc.
   Google Scholar
• Gu NY, Huang XY, Fox KM, et al. Claims data analysis of dosing and cost of TNF antagonists. Am J Pharm Benef 2010;2:351-9
   Google Scholar
• Harrison DJ, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Health- Syst Pharm 2010;67:1281-7
   PubMed Web of Science ®Google Scholar
• Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and meta-analysis of efficacy and safety. BMC Musculoskel Disord 2008;9:52
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Dahabreh IJ, Giannouli S, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Therap 2008;30:1939-55
   PubMed Web of Science ®Google Scholar
• Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biologics 2009;3:183-91
   PubMedGoogle Scholar
• Moots RJ, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exper Rheumatol 2011;29:26-34
   PubMed Web of Science ®Google Scholar
• Gilbert TD, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskel Disord 2004;5:36
   PubMed Web of Science ®Google Scholar
• Bullano MF, McNeeley BJ, Yu YF, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interf 2006;19:47-53
   PubMedGoogle Scholar
• Wu E, Chen L, Birnbaum H, et al. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin 2008;24:2229-40
   PubMed Web of Science ®Google Scholar
• Ollendorf DA, Klingman D, Hazard E, et al. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Therap 2009;31:825-35
   PubMed Web of Science ®Google Scholar
• Huang X, Gu NY, Fox KM, et al. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. Curr Med Res Opin 2010;26:1637-45
   PubMed Web of Science ®Google Scholar
• Flood J, Mihalik C, Fleming RR, et al. The use of therapeutic interchange for biologic therapies. Managed Care 2007;16:51-62
   Google Scholar
• Ogden CL, Fryar CD, Carroll MD, et al. Mean body weight, height, and body mass index, United States 1960–2002. Vital Health Stat 2004;347:1-17
   Google Scholar
• First DataBank. AnalySource Online. Wholesale Acquisition Cost (WAC). http://www.fdbhealth.com/fdb-medknowledge-drug-pricing. Accessed September 11, 2012
   Google Scholar
• Bonafede MK, Gandra SR, Fox KM, et al. Tumor necrosis factor- blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed care plans in the two years following therapy initiation. J Med Econ 2012;15:1-9
   Google Scholar
• Khanna D, Cyhaniuk A, Bedenbaugh A. Use of TNF inhibitors in the US: Utilisation patterns and dose escalation from a retrospective US RA population [abstract]. Ann Rheum Dis 2011;70(3 Suppl):197
   Google Scholar
• Blom M, Kievit W, Kuper HH, et al. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res 2010;62:1335-41
   PubMed Web of Science ®Google Scholar
• Schabert VF, Bruce B, Ferrufino CF, et al. Disability outcomes and dose escalation in rheumatoid arthritis patients treated with tumor necrosis factor blockers: a comparative effectiveness analysis [abstract PMS2]. Value Health 2010;13:A302
   Web of Science ®Google Scholar
• Segal SD, Power DJ, Smith DB, et al. Comparative effectiveness analysis of TNF blockers in rheumatoid arthritis (RA) patients in US community practice [abstract]. Ann Rheum Dis 2011;70(3 Suppl):252
   PubMedGoogle Scholar
• Etemad L, Yu EB, Wanke LA. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interf 2005;18:21-7
   PubMedGoogle Scholar